KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Liabilities (2018 - 2025)

Esperion Therapeutics' Total Liabilities history spans 8 years, with the latest figure at $767.9 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 4.82% year-over-year to $767.9 million; the TTM value through Dec 2025 reached $767.9 million, up 4.82%, while the annual FY2025 figure was $767.9 million, 4.82% up from the prior year.
  • Total Liabilities reached $767.9 million in Q4 2025 per ESPR's latest filing, down from $815.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $815.4 million in Q3 2025 to a low of $548.0 million in Q1 2021.
  • Average Total Liabilities over 5 years is $652.0 million, with a median of $619.1 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: soared 142.95% in 2021, then decreased 1.76% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $578.5 million in 2021, then decreased by 1.18% to $571.7 million in 2022, then rose by 15.58% to $660.8 million in 2023, then rose by 10.86% to $732.5 million in 2024, then rose by 4.82% to $767.9 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Total Liabilities are $767.9 million (Q4 2025), $815.4 million (Q3 2025), and $780.6 million (Q2 2025).